MBX Biosciences, Inc. (MBX)
| Market Cap | 817.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.20M |
| Shares Out | 33.38M |
| EPS (ttm) | -3.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,152 |
| Open | 23.09 |
| Previous Close | 23.16 |
| Day's Range | 23.05 - 25.31 |
| 52-Week Range | 20.29 - 26.08 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 16, 2024 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 cl... [Read more]
News
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel p...
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand...
MBX Biosciences shares surge 44% in blockbuster Nasdaq debut
Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, rose nearly 44% in their Nasdaq debut on Friday, underscoring i...
MBX Biosciences raises $163.2 mln in US IPO
MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial...
MBX Biosciences Announces Pricing of Initial Public Offering
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel p...
MBX Biosciences Announces Launch of Initial Public Offering
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the...
MBX Biosciences IPO Registration Document (S-1)
MBX Biosciences has filed to go public with an IPO on the NASDAQ.